Repligen Announces Asset Purchase Agreement With BioMarin for HDACi Portfolio

Repligen Announces Asset Purchase Agreement With BioMarin for HDACi Portfolio. Company Release - 01/21/2014 07:30. WALTHAM, Mass., Jan. 21, 2014 (GLOBE NEWSWIRE)

Repligen Corporation announced today that it has entered into an asset purchase agreement with BioMarin Pharmaceutical Inc. ("BioMarin") to advance Repligen's histone deacetylase inhibitor (HDACi) portfolio. Includes Preclinical Compounds for Potential Treatment of Friedreich's Ataxia